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Child sexual abuse (CSA) has not previously been regarded as
important in the overall transmission of HIV infection to
children.1,2 However, with both CSA3,4 and HIV infection on the
increase, the risk of acquiring HIV infection through CSA is
real, and several reports of such transmission have been
documented.5,6 The incidence in children of HIV acquired by
CSA is unknown, but the prevalence in Africa among sexually
abused children, mainly with penetrative injuries, ranges from
1% (2/200 children) in Cape Town, South Africa, to as high as
33.8% (24/71 children) in Cameroon.5,7 The author has
experience of at least 10 children who became HIV-infected
almost certainly through sexual abuse over the past 10 years.
Risk of HIV transmission by sexual
abuse
The risk of transmission during sexual abuse depends on
factors such as the HIV status of the perpetrator (mostly
unknown by the investigating team) and the child (although an
already infected child may be reinfected), the extent of
penetration and mucosal injury that occurs in the penetrated
orifice (vaginal, anal or oral), the presence of other sexually
transmitted infections (STIs), whether the perpetrator
ejaculated during the incident(s), and the number of exposures
to abuse. 
In adult women, the risk of transmission from one episode of
vaginal-penile contact is 0.1 - 0.2%, while the risk for
transmission during adult penile-anal contact is estimated at
0.1 - 3.0%.8 The risk of oral-genital contact is not known. In the
case of CSA the risk of transmission of HIV during a single
episode of abuse is unknown,8 but because of greater risk of
mucosal trauma, the risk is likely to be higher than in
consensual adult sexual contact. 
In a survey of children attending the Family Clinic for HIV
at Tygerberg Academic Hospital between 1997 and 2001, 5 of
274 children (1.8%) were infected through CSA (M F Cotton —
personal communication). Between 20% and 30% of infants
born to HIV-infected mothers become infected in the absence of
intervention. Should these children be victims of CSA it will be
difficult to establish whether HIV infection was vertically
transmitted or acquired by CSA if they had not been tested
previously. Molecular investigations such as phylogenetic
analyses have been used in some cases of suspected
transmission by CSA or other forms of unlikely transmission,
but this is expensive, not freely available, and difficult to
interpret because of rapid and continuous changes in the
virus.9,10
Screening for HIV in sexually abused
children
HIV counselling should be an integral part of the assessment of
all children who have suffered sexual abuse, if not for
screening, then at least to allay fears about HIV infection. In
itself CSA causes physical and/or psychological trauma and
children are often stigmatised. A possible further diagnosis of
HIV infection, whether sexually or otherwise acquired, will
certainly add to the trauma and stigmatisation experienced by
the individual and the family. Caregivers or young people will
have questions regarding HIV after CSA, and these should be
carefully considered and dealt with sensitively and without
delay.  All staff working with children who have suffered CSA
should therefore have a basic knowledge about HIV infection,
HIV post-exposure prophylaxis (PEP) and HIV care resources.
In sub-Saharan Africa, where the prevalence of HIV infection
is high, the need for testing will generally be greater than in
countries with a lower HIV prevalence. A careful history may
reveal potential risk factors regarding the abuse and the abuser
which might make testing more pertinent.2
Screening policies for HIV testing among sexually abused
children have varied from recommendations for selective
testing to recommendations for universal testing.6 Selective
recommendations seem to be more widely accepted. 
Table I summarises the circumstances in which HIV
serological testing in CSA have been recommended.1, 2, 6
HIV testing and informed consent
All parents/guardians of children under the age of 14 years,
and adolescents above 14 years of age with or without their
parents’ consent, presenting to a health facility after being
sexually abused should be counselled by the examining health
worker about the potential risk of HIV transmission. If the
child presents within 72 hours of being sexually abused,
antiretroviral drugs should be offered to prevent HIV
transmission.
The following points should be covered in the counselling:
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1. The risk of transmission through CSA is not known (see
above).
2. There is strong evidence to support the use of PEP in
preventing HIV transmission in occupational exposure.11-13
Although the effectiveness of PEP in non-occupational
exposure such as sexual abuse cases is not known, it is now
widely accepted on the basis of successes with occupational
PEP.11,14,15 However, HIV PEP is not a cure for HIV infection.
3. Acceptance of HIV PEP is voluntary. Acceptance of HIV
PEP requires the patient and/or caregiver to commit to
completing a 28-day regimen and a follow-up programme. The
importance of compliance should be emphasised.
4. The common adverse events of the drugs used should be
explained. Most adverse events are manageable, but rarely
these may be severe. Decisions to provide HIV PEP must
balance the potential benefits and risks.14,16 The adverse events
of antiretroviral drugs may be aggravated when taken with
other medication such as antituberculosis agents.
5. If parents/guardians request antiretroviral prophylaxis
more than 72 hours after sexual abuse, it should be explained
that this will have no impact on preventing HIV transmission.
Screening for CSA in HIV-infected
children
Health care workers should consider CSA as a possible reason
for acquisition of HIV infection especially in older children
diagnosed with HIV or in those whose mothers are HIV-
negative.6,17 In our experience most children do not readily
disclose that they have been sexually abused for a variety of
reasons. Several of our children have been identified as having
been sexually abused only after presenting with HIV infection
and its related complications. Others were seen as acute CSA
cases and initial HIV serological testing was done and found to
be negative, but no follow-up was arranged and they returned
years later with clinically evident HIV infection with no other
subsequent risk factors for transmission.
Testing of the perpetrator of CSA
Testing the alleged perpetrator is fraught with legal and ethical
issues regarding the rights and confidentiality of the
individual. Currently it seems that the HIV status of the
alleged perpetrator of CSA can only be tested if s/he is willing
to be tested, even if under arrest. The police cannot order a
health care worker to perform an HIV test unless the arrested
person consents. If the HIV status of the alleged perpetrator is
known to a doctor, the latter should be informed of the
situation and s/he may then ask the alleged perpetrator if this
information could be disclosed to the person managing the
child victim. If the perpetrator refuses, confidentiality can be
breached. The doctor should, however, first inform the
perpetrator that confidentiality is going to be breached in the
best interests of the child victim’s health.   
Prevention of HIV infection through
CSA
HIV post-exposure prophylaxis regimens
Zidovudine (AZT) and lamivudine (3TC) are currently
included in most HIV PEP regimens because of their
demonstrated reduction in HIV transmission in occupational
exposures and because they are generally well tolerated by
patients.11,18 With the roll-out of antiretroviral therapy in South
Africa, possible development of drug resistance should be
taken into account as in other countries, and some authors
advise substituting other nucleotide reverse transcriptase
inhibitors (NRTIs) for AZT and 3TC if it is known that the
source case has been taking these agents.19
Twice-daily regimens should be used where possible, and
HIV PEP should be administered as soon as possible (within
hours) after the abuse. Health care workers should not wait for
HIV test results before starting PEP if there is an indication for
its use. If the child is already known to be HIV-infected PEP
should not be given, but the child should be referred to an
appropriate HIV clinic for further management. If the initial
HIV test is positive, or by further evaluation of the case it
becomes clear that PEP is not indicated, prophylaxis can be
discontinued. Prophylaxis is also not indicated if the child
presents more than 72 hours after the incident.
Although some authors recommend a two-drug regimen
(AZT plus 3TC) as HIV PEP in some circumstances, most
guidelines recommend a three-drug regimen (two NRTIs plus a
protease inhibitor).11,14,18 Protease inhibitors are the main item of
controversy in HIV PEP regimens because they are more
expensive, have more unpleasant adverse events, and their
benefit in PEP has not yet been established.11 Drugs and doses
are summarised in Table II. 
Children and adolescents started on HIV PEP should receive
sufficient medication for 3 - 7 days and be seen for follow-up
within this period to assess adherence and tolerance of the
regimen. If the regimen is tolerated and they are adherent to
therapy, the rest of the 28-day PEP course should be supplied. 
Follow-up HIV testing
All sexually abused children should be followed up in a health
care setting where appropriate medical and counselling
resources are available. In those who are at risk for HIV
transmission serological testing should be performed at 4 - 6
weeks, and at 3 and 6 months after exposure. In our experience
both compliance with prophylaxis regimens and follow-up
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remain major problems in the effective management of these
children.
Prevention of CSA
A clear message should be proclaimed by all political and
community leaders that CSA is unacceptable and inexcusable.
More effective medical examinations, police and social work
investigations and successful prosecutions with the appropriate
punishments could deter many male perpetrators from CSA.20
Myths regarding the cure of STDs and particularly HIV by
having sex with a virgin, a mistaken belief still held by many,
must be opposed vigorously.21,22 More complex, but no less
important in curbing CSA, are issues of gender inequality with
women and children being the victims, extreme levels of
poverty, and disruption of families. 
Disclosure of diagnosis to an HIV-
infected child
There is an understandable fear among parents of disclosing
the HIV status to their children in the case of vertically
transmitted HIV, as the disease is still very much stigmatised
and parents fear that children will reveal their status to their
friends and in this way to the community.23 According to
reports mainly from Western countries, the majority of parents
reveal the status to their children from about 8 - 10 years of
age.24
Children infected with HIV through CSA are generally older
and mothers are mainly HIV-negative.6 Disclosure to these
children could be as difficult even though this might not be a
family disease. No reports on disclosure to sexually abused
children could be identified. 
Honesty probably remains the most important component of
disclosure together with a well-established support system to
which the family and/or child could turn. Neither parents nor
health workers want inadvertently to inflict more suffering on
a child than is already present from the abuse and illness
itself.25 However, according to the American Academy of
Pediatrics there does not appear to be evidence to support the
fear that disclosure of HIV infection to children will cause
negative consequences.26 Disclosure may be advantageous in
that it allows for better understanding of the illness, more open
involvement in medical care decisions, increased opportunities
for support and improved trust in the health care providers.27,28
Children often suspect their HIV status long before
disclosure.25 However, disclosure remains a difficult task, best
managed by parents together with a paediatric HIV
interdisciplinary team, involving at least medical staff, social
workers, psychologists and psychiatrists, and trained
counsellors. Gerson et al.25 describe in detail the successful
process of disclosure used at their institution using the
following framework: (i) information gathering and trust
building; (ii) education; (iii) determining when the time is right
for disclosure; (iv) the actual disclosure event; and (v)
monitoring post-disclosure coping and managing disclosure-
related problems or challenges. 
The final decision when to disclose remains with the parent
Table I. Summary of circumstances in which HIV testing is
recommended1,2,6
Recommendations for HIV serological testing in child sexual
abuse cases
1. The child has another acquired sexually transmitted disease
2. The child has an anal or a vaginal injury or discharge or
other mucosal injury suggestive of abuse
3. The child has been documented to have experienced penile
invasive abuse
4. The child is reported for suspected CSA and outcome is
confirmed, suspected or unknown
5. The child is exposed to a known HIV-infected perpetrator of
abuse or a perpetrator with unknown HIV status, especially
if risk factors are identified, such as clinical findings of HIV
infection, previously having served a prison sentence,
intravenous drug user and multiple sexual partners
6. The child was abused by multiple assailants
7. The child has clinical findings compatible with HIV infection
8. Frequent exposure to abuse
9. A history of high-risk behaviour in an adolescent
10. Parent or young person requesting testing
Table II. HIV post-exposure prophylaxis regimen for sexually
abused children
Age group and 28-day antiretroviral regimen —  drug 
and dose
≥ 13 years of age (≥ 35 - 40 kg)
*Zidovudine/lamivudine combination (Combivir) 
1 tablet twice daily
plus (risk and availability dependent)
†Lopinavir/ritonavir (Kaletra)   > 12 years or > 40 kg:   5 ml or
3 capsules twice daily
< 13 years of age
*Zidovudine 180 mg/m2 body surface area/dose orally twice 
daily (maximum 300 mg/dose)
plus
*Lamivudine 4 mg/kg/dose orally twice daily (maximum 
150 mg/dose)
plus (risk and availability dependent)
†Lopinavir/ritonavir (Kaletra) 
6 months - 12 years: 7 - 15 kg: 12 mg/kg twice daily
Up to 12 years: 15 - 40 kg: 10 mg/kg twice daily
> 12 years or > 40 kg: 5 ml or 3 capsules twice daily
* Possible alternative nucleoside reverse transcriptase inhibitors (NRTIs)
Abacavir (Ziagen) 8 mg/kg/dose orally twice daily (maximum 
300 mg/dose)
Didanosine (ddI/Videx) 90 - 150 mg/m2/dose orally twice daily (maximum
200 mg/dose)
Stavudine (d4T/Zerit) 1 mg/kg/dose orally twice daily (maximum 30 mg 
from 30 - 60 kg)
†Possible alternative protease inhibitors
Nelvinavir (Viracept) 1 250 mg (5 x 250 mg tablets) twice daily
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or caregiver, but they mostly need help. The sharing of difficult
news with children is complicated, but health care providers
should take on this responsibility and be prepared.
Disclosing of their HIV status to their friends or peers is
another aspect of disclosure in which children need guidance.
They should be warned not to be indiscriminate in telling peers
that they have HIV. Although some reports show a positive
clinical effect with disclosure to trusted friends, such as a rise
in CD4 count, others warn that disclosure often has a negative
psychological impact.25,29
Long-term consequences of CSA
Many studies have shown that CSA in both girls and boys is
linked to health problems in adolescence and adulthood,
including risky sexual behaviour, more sexually transmitted
diseases, and injection drug use.30-33 Currently, the focus is
usually on the individual child’s sexual abuse, but future
treatment should also aim much more at addressing family
function and the child’s feelings of despair.
Conclusion
The role of CSA as a cause of HIV infection in children is
underestimated and needs further research, especially in
countries with high HIV prevalence. All possible means should
be used to prevent CSA in our communities. However, when
prevention fails and children become victims of this crime, the
least we can do is to try and prevent the serious consequences
such as HIV infection with all the means we have available. 
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